Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

sociates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References

  1. Hoeper M, et al. Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). Data presented at the European Respiratory Society (ERS) Annual Congress. Abstract No. 413. Presented September 25, 2011, Room D203-204.
  2. Schermuly RT, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21.
  3. Novartis data on file.
  4. National Heart and Lung Blood Institute. National Institute of Health.  What is Pulmonary Hypertension? Available at http://www.nhlbi.nih.gov/health/health-topics/topics/pah/.  Accessed September 14, 2011.
  5. Provencher S, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006;27:589–95.
  6. Miyamoto S, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–492.
  7. Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:869–903.
  8. Galiè N, et al.Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148–2157.
  9. Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
  10. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest. 2005;115:2691
    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 Steven Rash , the CEO ... its operating subsidiary American Seed & Oil Company, presented ... investors yesterday in New York City.  Mr. Rash,s presentation ... American Seed & Oil Company has recently announced the ... Hemp Seed Foods , the EpiVape , and ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) has announced ... in 2014 - a Perspective of Mental Health Patient ... For the first time, in 2014, the ... the pharmaceutical industry held by patient groups with an ... organisations representing all therapy areas. - Findings ...
(Date:4/16/2015)... April 16, 2015 Mindray Medical International ... and marketer of medical devices worldwide, announced today ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2014. An electronic version of Mindray,s Annual ... investor relations website at  http://ir.mindray.com  or  http://www.sec.gov . ...
Breaking Medicine Technology:American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... May 22 Shire plc (LSE: SHP, Nasdaq: ... results of a study showing that coadministration of the ADHD ... (PPI) Prilosec OTC(R) 40 mg (20 mg X 2), did ... concentration of d -amphetamine to be reached in the ...
... Calif., May 21 Telik, Inc. (Nasdaq: TELK ... study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal ... annual meeting of the American Society of Clinical Oncology (ASCO) ... in Orlando, FL.Details of the presentation are as follows:, ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog post explaining how ... . , The online environment can help many ... should always compare multiple car insurance policies before deciding ... competitive one, which means that customers can find new ... now possible to compare online car insurance quotes on ...
(Date:4/17/2015)... 2015 Lowcostcarinsuranceprice.com has released a new blog ... its effects on car insurance rates . , ... past accidents can have a big impact on auto insurance ... an accident and claimed benefits. The newly released blog post ... prevent such accidents. , It is now possible to ...
(Date:4/17/2015)... 2015 Ticket Down is a reputable source of ... Tour. , The life of last-minute show announcements is where fans ... perform during the early part of 2015, but beginning in June, ... Lion Man,” “The Cave,” and “Believe,” will perform a full-fledged tour ... at MCU Park at Coney Island in Brooklyn, NY and ends ...
(Date:4/17/2015)... April 17, 2015 Verndale, a Global ... has once again been chosen as a Boston Business ... private company in the region. The BBJ’s Pacesetters represents ... from 2011 through 2014. This is the eighth consecutive ... years that Verndale has been honored with this award. ...
(Date:4/17/2015)... 2015 TouchCare is releasing a product update ... and their patients to use their smartphones to quickly and ... version has a completely redesigned interface which enables a provider ... a patient to connect for a secure video call in ... available on Android as well as iOS with a simple ...
Breaking Medicine News(10 mins):Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Accidents Caused By Sleeping at The Wheel Can Increase Auto Insurance Costs 2Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2Health News:Verndale Honored as 2015 Boston Business Journal Pacesetter, Named 46th Fastest Growing Private Company 2Health News:TouchCare Now Connects Android Users to Their Doctors, And Delivers Sleek New Interface For All 2Health News:TouchCare Now Connects Android Users to Their Doctors, And Delivers Sleek New Interface For All 3
... looks to kill cells on organ,s surface, spare ... -- Patients are being recruited for a clinical trial ... pleural mesothelioma, a cancer of the lung,s lining that,s ... the standard treatment is to remove the affected lung. ...
... reduce hot flashes effectively. The good news is that cool herbs ... , ... Ann Arbor, MI (PRWEB) July 21, 2008 -- The hot summer ... merits of synthetic or bio-identical hormones. Too much complicated information overwhelms menopause ...
... the immune system interact, scientists at The Feinstein Institute for Medical Research ... spleen communicate. , ... Manhasset, NY (PRWEB) July 21, 2008 -- In ... system interact, scientists at The Feinstein Institute for Medical Research ...
... who need to be concerned about the heavily polluted ... cardiovascular problems for some spectators. , Two researchers ... Feinberg School of Medicine warn that for people in ... cause heart attacks and strokes within 24 hours of ...
... Kennedy DSc, Dean of Tufts University,s Gerald J. and ... announced the 3rd Annual Friedman School Symposium, a conference ... industry, policy-makers, academics and thought leaders in the coming ... 24th to 26th, 2008. , Fifteen experts will present ...
... healthy meals for less, , , MONDAY, July 21 (HealthDay News) ... your car, groceries are likely the next biggest expense in ... more and more of the average Americans income. , ... Then, in just the first five months of 2008, ...
Cached Medicine News:Health News:Lung Cancer Trial Targets Asbestos-Related Disease 2Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 2Health News:Menopause: Hot Flashes Can Be Reduced 90% without Hormones 3Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 2Health News:Embargoed Until Monday, July 21 at 5 p.m. EST; Scientists Figure Out How the Immune System and Brain Communicate to Control Disease 3Health News:Beijing pollution may trigger heart attacks, strokes 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 2Health News:'Nutrition Agenda 2008' is focus of Tufts Friedman School Symposium 3Health News:Stretch That Grocery List in Lean Times 2Health News:Stretch That Grocery List in Lean Times 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: